Pre-Profiled Anti Cancer Drugs
Anti Cancer Drugs List for Comparative Profiling, GeneNominator™ and SynergyFinder™
Compound |
Synonym |
Target |
||
|---|---|---|---|---|
| 2-D08 | SUMOylation | |||
| 5-fluorouracil | 5-FU, Adrucil, Carac, Efudex | thymidylate synthase | ||
| 6-thioguanine | 6-TG | purine antimetabolite | ||
| A-1210477* | BH3 mimetic for Mcl-1 | |||
| A-420983 | LCK | |||
| abemaciclib | LY2835219, Verzenio, Verzenios | CDK4/6 | ||
| ABT-737 | Bcl-2 | |||
| acalabrutinib | ACP-196, Calquence | BTK | ||
| actinomycin-D | dactinomycin, Cosmegen | interfering with mRNA synthesis | ||
| adavosertib | MK1775, AZD1775 | Wee | ||
| afatinib | BIBW 2992, Gilotrif, Giotrif, Afanix | EGFR, ErbB2 | ||
| alectinib | CH5424802, Alecensa | ALK | ||
| all-transretinoic-acid | ATRA, Tretinoin, Vesanoid, Avita, Renova, Retin-a | PML-RAR protein | ||
| alpelisib | BYL719, Piqray | PI3Kα | ||
| AMG-510 | KRAS G12C | |||
| AMG-900 | pan Aurora | |||
| anacardic acid* | SUMOylation | |||
| apitolisib | GDC 0980 | PI3Kα/ß/δ/γ | ||
| APR-246 | p53 activator, PRIMA1-analog | |||
| ARQ-531 | BTK | |||
| AT-7519 | CDK1/2/4/6/9 | |||
| AT-9283 | JAK2/3 | |||
| axitinib | AG-013736, Inlyta, Axinix | VEGFR1/2/3, PDGFRß, c-Kit | ||
| AZD-8055 | mTOR | |||
| BAY293 | KRAS-SOS1 | |||
| BAY-320 | Bub1 | |||
| BAY11-7085 | NFkB | |||
| BI-2536 | Plk1 | |||
| BIIB 021 | CNF 2024 | HSP90 | ||
| BLU-9931 | FGFR4 | |||
| bortezomib | PS-341, Velcade, Chemobort, Bortecad | proteasome | ||
| bosutinib | SKI-606, Bosulif | Src, Abl | ||
| brigatinib | AP26113, Alunbrig, Briganix | ALK, EGFR | ||
| brivanib | BMS-540215 | VEGFR, FGFR, IGFR1 | ||
| buparlisib | BKM-120, NVP-BKM120 | PI3K_p110α/ß/δ | ||
| busulfan | Myleran, Busilvex, Busulfex IV | chemotherapy | ||
| cabozantinib | XL 184, BMS 907351, Cabometyx, Cometriq, Cabozanix | VEGFR2, c-Met, Ret, Kit, Flt-1/3/4, Tie2, AXL | ||
| camptothecin | CPT | topoisomerase I | ||
| capecitabine* | Xeloda | thymidylate synthase | ||
| carboplatin | Paraplatin | DNA | ||
| carfilzomib | PR-171-007, Kyprolis | proteasome | ||
| CB-1158* | INCB001158 | arginase | ||
| ceritinib | LDK 378, Zykadia | ALK | ||
| CHIR-124 | Chk1 | |||
| cisplatin | CDDP, Platinol | DNA | ||
| cobimetinib | GDC-0973, XL-518, Cotellic | MEK1 | ||
| copanlisib | BAY 80-6946, Aliqopa | PI3K, AKT, mTOR | ||
| crenolanib | FLT3, PDGFRα/ß | |||
| crizotinib | PF-02341066, Xalkori, Crizonix | c-Met, ALK | ||
| CYC116 | Aurora, VEGFR2 | |||
| cytarabine | ara-C, Cytosar-U, Depocyt | DNA synthesis inhibitor | ||
| dabrafenib | GSK2118436, Tafinlar | B-RAF | ||
| dacarbazine | imidazole carboxamide, DTIC-Dome | chemotherapy | ||
| dacomitinib | PF-299804, PF299, Vizimpro | EGFR | ||
| dactolisib | BEZ235, NVP-BEZ235 | PI3K, mTOR, ATR | ||
| danusertib | PHA-739358 | pan Aurora | ||
| dasatinib | BMS-354825, Sprycel, Dasanix | Abl, Src, c-Kit | ||
| daunorubicin | daunomycin, Cerubidine | DNA, RNA synthesis | ||
| degrasyn | WP1130 | USP9x/5/14, UCH37, other activity (Bcr/Abl) | ||
| derazantinib | ARQ 087, BAL087 | FGFR2 | ||
| dinaciclib | SCH727965 | CDK1/2/5/9 | ||
| docetaxel | RP56976, DTX, DXL, Taxotere, Docecad | microtubule | ||
| doxifluridine | 5-dFdU | nucleoside analog prodrug | ||
| doxorubicin | Adriamycin, Caelyx, Myocet | topoisomerase II | ||
| duvelisib | IPI-145, Copiktra | PI3Kδ/γ | ||
| entinostat | MS-275, SNDX-275 | HDAC1/3 | ||
| entrectinib | RXDX-101, NMS-E628, Rozlytrek | TrkA, TrkB, RrkC, ROS1, ALK | ||
| epirubicin | Ellence, Pharmorubicin, Epirubicin Ebewe | topoisomerase II | ||
| epothilone B | EPO906, patupilone | microtubule | ||
| EPZ-005687* | EZH2, ARID1A | |||
| erdafitinib | JNJ-42756493, Balversa | FGFR | ||
| eribulin | E7389, ER 086526, Halaven | tubulin | ||
| erismodegib* | NVP-LDE-225 | Smo, Hedgehog | ||
| erlotinib | Tarceva | EGFR | ||
| etoposide | VP16, Etopophos, Toposar | topoisomerase II | ||
| everolimus | RAD001, Zortress, Certican, Afinitor, Votubia, Evertor | mTOR inhibitor of FKBP12 | ||
| fasudil* | HA-1077 | ROCK-II, PKA, PKG, PKC, MLCK | ||
| fenebrutinib | GDC-0853, FEN | BTK | ||
| fosfamatinib | Tavalisse, Tavlesse | prodrug of tamatinib, Syk | ||
| fulvestrant | Faslodex | oestrogen receptor antagonist | ||
| GDC-0152 | XIAP, IAP | |||
| gefitinib | ZD1839, Iressa | EGFR | ||
| gemcitabine | Gemzar | DNA synthesis inhibitor | ||
| gilteritinib | FLT3, AXL | |||
| GSK-1070916 | Aurora B/C | |||
| GSK-126 | EZH2, ARID1A | |||
| GSK-1838705A | IGF-1R, IR, ALK | |||
| GSK-343 | EZH2, ARID1A | |||
| GSK-461364 | Plk1 | |||
| ibrutinib | PCI-32765, Imbruvica, Ibrutix | BTK | ||
| ICG-001 | antagonizes Wnt/ß-catenin, TCF-mediated transcription and specifically binds to element-binding protein (CBP) | |||
| idelalisib | CAL-101, GS-1101, Zydelig | PI3Kγ | ||
| imatinib | STI-571, Gleevec, Glivec | v-Abl, c-Kit, PDGFR | ||
| infigratinib | BGJ-398, NVP-BGJ-398 | FGFR1/2/3 | ||
| ipatasertib | GDC-0068, RG7440 | Akt | ||
| irbinitinib | tucatinib, ARRY-380, ONT-380 | ErbB2 | ||
| irinotecan | Camptosar, Campto, Onivyde | topoisomerase I | ||
| JQ1 | BET bromodomain inhibitor, BRD4 | |||
| KU-60019 | ATM | |||
| lapatinib | GSK-572016, Tykerb, Tyverb | EGFR, ErbB2 | ||
| larotrectinib | LOXO-101, ARRY-470, Vitrakvi | TrkA, TrkB, TrkC | ||
| LB42708 | farnesyltransferase | |||
| lenvatinib | E7080, Lenvima, Lenvanix | VEGFR | ||
| LGK-974 | porcupine (Wnt signaling antagonist) | |||
| lorlatinib | PF-6463922, Lorbrena, Lorviqua | ALK, ROS1 | ||
| macitentan* | Opsumit | ETA, ETB receptor | ||
| masitinib | AB1010, Masivet, Kinavet | Kit, PDGFRα/ß | ||
| melphalan | Alkeran, Evomela, Sarcolysin | alkylating agent | ||
| mercaptopurine | 6-MP, 6-mercaptopurine, Purinethol | purine synthase | ||
| methotrexate | amethopterin, Trexall, Rheumatrex | dihydrofolate reductase (DHFR) | ||
| MG132 | proteasome | |||
| midostaurin | PKC412, Rydapt | FLT3 | ||
| mitomycin-C | DNA crosslinker | |||
| mitoxantrone | mitozantrone, Novantrone | topoisomerase II | ||
| MK-2206 | Akt1/2/3 | |||
| MK-5108 | VX-689 | Aurora A | ||
| ML-792 | SUMOylation | |||
| MLN-7243 | TAK-243 | ubiquitin-activating enzymes, E1 | ||
| MLN-8054 | Aurora A | |||
| momelotinib | GS-0387, CYT-387 | JAK1/2, TBK1 | ||
| molibresib | I-BET-762, GSK-525762 | BET proteins | ||
| MPI-0479605 | TTK (MPS1) | |||
| MPS1-IN-1 | TTK (MPS1) | |||
| MRK-560 | gamma secretase | |||
| mubritinib | TAK165 | ErbB2 | ||
| navitoclax | ABT-263 | Bcl-xL, Bcl-2, Bcl-w | ||
| neratinib | HKI-272, Nerlynx, Hernix | EGFR, ErbB2 | ||
| nilotinib | AMN-107, Tasigna | Bcr-Abl | ||
| nintedanib | BIBF 1120, Vargatef, Ofev | triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3, PDGFRa/ß | ||
| niraparib | MK-4827, Zejula | PARP | ||
| NMS-P715 | TTK (MPS1) | |||
| nutlin 3a | P53wt | |||
| NVP-ADW742 | IGF-1R | |||
| obatoclax | GX15-070 | Bcl-2 | ||
| olaparib | AZD-2281, MK-7339, Ku-0059436, Lynparza | PARP1/2 | ||
| osimertinib | merelitinib, Tagrisso, Tagrix | EGFR | ||
| paclitaxel | Taxol | microtubule | ||
| palbociclib | PD 0332991, Ibrance | CDK4/6 | ||
| panobinostat | LBH 589, Farydak | HDAC | ||
| pazopanib | GW786034, Votrient | VEGFR1/2/3, PDGFR, FGFR, c-Kit, c-Fms | ||
| PD-0325901 | MEK | |||
| pelitinib | EKB-569 | EGFR | ||
| pemigatinib | Pemazyre | FGFR2 | ||
| pevonedistat | MLN4924 | NEDD8 | ||
| pexidartinib | PLX3397, Turalio | FMS (CSF-1R), KIT | ||
| PHA-793887 | CDK2/5/7 | |||
| pictilisib | GDC-0941 | PI3Kα/δ | ||
| pilaralisib* | XL-147 | PI3Kα/δ/γ | ||
| pinometostat* | EPZ-5676 | methyltransferase DOT1L | ||
| ponatinib | AP24534, Iclusig | Abl, PDGFRa, VEGFR2, FGFR1, Src | ||
| prednisolone | GR | |||
| quizartinib | AC220 | FLT3 | ||
| regorafenib | BAY 73-4506, Stivarga, Regonix | VEGFR1/2/3, PDGFRß, Kit, RET and Raf-1 | ||
| reversine | A3 adenosine receptor antagonist, pan Aurora, TTK | |||
| ribociclib | LEE-011, Kisqali | CDK4/6 | ||
| rucaparib | PF-01367338, AG014699, Rubraca | PARP | ||
| ruxolitinib | INCB018424, INC424, Jakafi, Jakavi | JAK1/2 | ||
| SCH-900776 | MK-8776 | Chk1 | ||
| seliciclib* | CYC202, roscovitine | CDK | ||
| selumetinib | AZD6244, ARRY-142886 | MEK1 | ||
| SGX-523* | Met | |||
| SN-38 | topoisomerase I, active metabolite of CPT-11 | |||
| sonidegib* | NVP-LDE-225, erismodegib | Smo, Hedgehog | ||
| sorafenib | sorafenib tosylate, Nexavar | Raf-1, B-Raf, VEGFR-2 | ||
| STLC | S-trityl-L-cysteine | kinesin Eg5 | ||
| streptozocin* | streptozotocin, Zanosar | ribosome | ||
| sunitinib | SU11248, Sutent | VEGFR2 (Flk-1), PDGFRß, c-Kit | ||
| talazoparib | BMN-673, Talzenna | PARP | ||
| tamatinib | R-406 | Syk | ||
| taselisib | GDC-0032 | PI3K mutant | ||
| tazemetostat | EPZ-6438, Tazverik | EZH2, ARID1A | ||
| temozolomide* | Temodar, Temodal, Temcad | DNA damage inducer | ||
| temsirolimus | CCI-779, NSC 683864, Torisel | mTOR | ||
| TGX-221 | PI3K | |||
| TH-588 | microtubule (formerly reported as MTH1 (NUDT1) inhibitor) | |||
| tivozanib | AV-951, Fotivda | VEGFR | ||
| tofacitinib | CP-690550, Xeljanz, Jakvinus, Tofacinix | JAK3 | ||
| tomivosertib | eFT508 | MNK1/2 | ||
| topotecan | Hycamtin | topoisomerase I | ||
| tozasertib | VX-680 | pan-Aurora | ||
| trametinib | Mekinist, GSK1120212 | MEK1/2 | ||
| trastuzumab | Herceptin, Herzuma | HER2 | ||
| trastuzumab emtansine | ado-trastuzumab emtansine, Kadcyla | HER2 | ||
| ulixertinib | BVD-523, VRT752271 | ERK1/2 | ||
| UMI-77 | Mcl-1, Bcl-2 | |||
| UNC-1999 | EZH2, ARID1A | |||
| vandetanib | ZD6474, Caprelsa | VEGFR2 | ||
| vatalanib* | PTK787, PTK/ZK | VEGFR2, KDR | ||
| vecabrutinib | SNS-062 | BTK, ITK | ||
| vemurafenib | PLX4032, RG7204, RO5185426, Zelboraf | B-RAF | ||
| venetoclax* | GDC-0199, ABT-199, RG7601, Venclexta, Venclyxto | Bcl-2 | ||
| vinblastine | vincaleukoblastine, Velban | mitosis | ||
| vincristine | leurocristine, Oncovin, Vincasar | tubulin | ||
| vinflunine | Javlor | tubulin | ||
| volasertib | BI 6727 | PLK1 | ||
| vorinostat | suberanilohydroxamic acid, SAHA, MK0683, Zolinza | HDAC | ||
| XAV-939 | tankyrase1/2 | |||
| zanubrutinib | BGB-3111, Brukinsa | BTK | ||
Compounds with an asterisk (*) are excluded from the comparative analysis.
